Cervical Cancer Screening Cascade for Women Living with HIV: a Cohort Study from Zimbabwe
Overview
Authors
Affiliations
Countries with high HIV prevalence, predominantly in sub-Sahahran Africa, have the highest cervical cancer rates globally. HIV care cascades successfully facilitated the scale-up of antiretroviral therapy. A cascade approach could similarly succeed to scale-up cervical cancer screening, supporting WHO's goal to eliminate cervical cancer. We defined a Cervical Cancer Screening Cascade for women living with HIV (WLHIV), evaluating the continuum of cervical cancer screening integrated into an HIV clinic in Zimbabwe. We included WLHIV aged ≥18 years enrolled at Newlands Clinic in Harare from June 2012-2017 and followed them until June 2018. We used a cascade approach to evaluate the full continuum of secondary prevention from screening to treatment of pre-cancer and follow-up. We report percentages, median time to reach cascade stages, and cumulative incidence at two years with 95% confidence intervals (CI). We used univariable Cox proportional hazard regressions to calculate cause-specific hazard ratios with 95% CIs for factors associated with completing the cascade stages. We included 1624 WLHIV in the study. The cumulative incidence of cervical screening was 85.4% (95% CI 83.5-87.1) at two years. Among the 396 WLHIV who received screen-positive tests in the study, the cumulative incidence of treatment after a positive screening test was 79.5% (95% CI 75.1-83.2) at two years. The cumulative incidence of testing negative at re-screening after treatment was 36.1% (95% CI 31.2-40.7) at two years. Using a cascade approach to evaluate the full continuum of cervical cancer screening, we found less-than 80% of WLHIV received treatment after screen-positive tests and less-than 40% were screen-negative at follow-up. Interventions to improve linkage to treatment for screen-positive WLHIV and studies to understand the clinical significance of screen-positive tests at follow-up among WLHIV are needed. These gaps in the continuum of care must be addressed in order to prevent cervical cancer.
Extensive cervical lesion and treatment outcomes in women with HIV/HPV co-infection.
Mngqibisa R, Chen H, Godfrey C, Sebitloane M, Chakalisa U, Badal-Faesen S AIDS Res Ther. 2024; 21(1):101.
PMID: 39736742 PMC: 11684313. DOI: 10.1186/s12981-024-00693-6.
Lee J, Ismail-Pratt I, Machalek D, Kumarasamy S, Garland S PLOS Glob Public Health. 2024; 4(10):e0003768.
PMID: 39365795 PMC: 11451976. DOI: 10.1371/journal.pgph.0003768.
Rasmussen P, Hoffman R, Phiri S, Makwaya A, Kominski G, Bastani R BMC Health Serv Res. 2024; 24(1):792.
PMID: 38982430 PMC: 11234730. DOI: 10.1186/s12913-024-11226-2.
Asangbeh-Kerman S, Davidovic M, Taghavi K, Dhokotera T, Manasyan A, Sharma A J Int AIDS Soc. 2024; 27(7):e26303.
PMID: 38979918 PMC: 11232047. DOI: 10.1002/jia2.26303.
Effah K, Anthony R, Tekpor E, Amuah J, Wormenor C, Tay G Cancer Control. 2024; 31:10732748241244678.
PMID: 38563112 PMC: 10989037. DOI: 10.1177/10732748241244678.